{"schema_version":"1","generated_at":"2026-10-30T16:41:53.875Z","data_as_of":null,"url":"https://www.findmykol.com/kol/thierry-jahan","json_url":"https://www.findmykol.com/kol/thierry-jahan/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"thierry-jahan","name":"Thierry Jahan","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of California, San Francisco","institution_url":"https://www.findmykol.com/institution/university-of-california-san-francisco","city":"San Francisco","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1427007657","openalex":"A5110482662"},"summary":"Thierry Jahan is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 152 publications with 10,743 citations (h-index 41); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":152,"cited_by_count":10743,"h_index":41,"latest_activity_year":2021,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00053885","title":"PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"Alliance for Clinical Trials in Oncology","source_url":"https://clinicaltrials.gov/study/NCT00053885","trial_url":"https://www.findmykol.com/trial/NCT00053885"}],"source":"trials"},"prescribing":{"data_year":2020,"areas_total":3,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":50,"classes_total":1,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":50,"drugs":[{"name":"Tagrisso","share_pct":100}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":27.4,"classes_total":1,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":27.4,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":22.6,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":22.6,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2020,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","year":2021,"journal":"The Lancet","source_url":"https://doi.org/10.1016/s0140-6736(20)32714-8","status":"verified"},{"title":"Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing","year":2020,"journal":"Cell","source_url":"https://doi.org/10.1016/j.cell.2020.07.017","status":"verified"},{"title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study","year":2020,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(20)30451-4","status":"verified"},{"title":"ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743","year":2020,"journal":"Journal of Thoracic Oncology","source_url":"https://doi.org/10.1016/j.jtho.2020.08.004","status":"verified"},{"title":"Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma","year":2019,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-19-0070","status":"verified"}],"source":"works"},"contact":{"address_1":"1600 DIVISADERO ST","city":"San Francisco","state":"CA","zip":"941153010","phone":"415-353-9888","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1427007657","source":"identity"},"similar":[{"name":"Adil Daud","slug":"adil-daud","institution":"University of California, San Francisco","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/adil-daud","json_url":"https://www.findmykol.com/kol/adil-daud/profile.json"},{"name":"Emmanuelle Waubant","slug":"emmanuelle-waubant","institution":"University of California, San Francisco","specialty":"Neurology","url":"https://www.findmykol.com/kol/emmanuelle-waubant","json_url":"https://www.findmykol.com/kol/emmanuelle-waubant/profile.json"},{"name":"Peter Ganz","slug":"peter-ganz","institution":"University of California, San Francisco","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/peter-ganz","json_url":"https://www.findmykol.com/kol/peter-ganz/profile.json"},{"name":"Joel Palefsky","slug":"joel-palefsky","institution":"University of California, San Francisco","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/joel-palefsky","json_url":"https://www.findmykol.com/kol/joel-palefsky/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2012-08-30","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2020}},"methodology_url":"https://www.findmykol.com/about#methodology"}